Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: the example of NOACs in atrial fibrillation.
Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal. Electronic address: dgcaldeira@hotmail.com.
Daniel
D
Caldeira
Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal; Evidence Based Medicine Centre, Faculty of Medicine, University of Lisbon, Portugal; Portuguese Collaborating Centre of the Cochrane Iberoamerican Network, Faculty of Medicine, University of Lisbon, Portugal.
João
J
Costa
Clinical Pharmacology Unit, Instituto de Medicina Molecular, Lisbon, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal.
Joaquim J
JJ
Ferreira
Cardiology Department, CCUL, CAML, Faculty of Medicine, Lisbon, Portugal.
Fausto J
FJ
Pinto
D001281:Atrial Fibrillation / Q000150:complications*; D002986:Clinical Trials as Topic / Q000592:standards*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D013927:Thrombosis / Q000209:etiology* / Q000517:prevention & control*; D016896:Treatment Outcome
D005343:Fibrinolytic Agents
Apixaban; Dabigatran; Edoxaban; Net clinical benefit; Rivaroxaban; Safety